Cargando…
Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study
BACKGROUND: Acute hepatic porphyria (AHP) is a family of four rare genetic diseases, each involving deficiency in a hepatic heme biosynthetic enzyme. Resultant overproduction of the neurotoxic intermediates δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral...
Autores principales: | Wang, Bruce, Ventura, Paolo, Takase, Kei-ichiro, Thapar, Manish, Cassiman, David, Kubisch, Ilja, Liu, Shangbin, Sweetser, Marianne T., Balwani, Manisha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9419398/ https://www.ncbi.nlm.nih.gov/pubmed/36028858 http://dx.doi.org/10.1186/s13023-022-02463-x |
Ejemplares similares
-
Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study
por: Ventura, Paolo, et al.
Publicado: (2021) -
EXPLORE B: A prospective, long‐term natural history study of patients with acute hepatic porphyria with chronic symptoms
por: Cassiman, David, et al.
Publicado: (2022) -
Porphyrias in the Age of Targeted Therapies
por: Erwin, Angelika L., et al.
Publicado: (2021) -
AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review
por: Wang, Bruce, et al.
Publicado: (2023) -
Acute Hepatic Porphyria
por: Bissell, D. Montgomery, et al.
Publicado: (2015)